{"entity":{"id":"ian-krop","kind":"person","name":"Ian E. Krop","aka":[],"tldr":"Breast oncologist who took T-DM1 and then trastuzumab deruxtecan from first-in-human studies to approval.","summary":"Ian Krop (Yale Cancer Center) led the early development of trastuzumab emtansine including its phase 1 and TH3RESA trials, and was a lead investigator of the DESTINY-Breast programme that made trastuzumab deruxtecan standard second-line therapy for HER2-positive disease. He chairs the Translational Breast Cancer Research Consortium and leads early-phase ADC trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krop%20IE%5BAuthor%5D%20trastuzumab%20emtansine%20OR%20deruxtecan"}],"tags":["breast","adc","her2"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-emtansine","trastuzumab-deruxtecan"],"companies":[],"institutions":["yale-cancer-center"],"pathways":[],"terms":[],"trials":["destiny-breast03"],"people":[],"bottlenecks":[],"keyPapers":["paper-destiny-breast03-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Cancer Center Director for Clinical Research, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["HER2-positive breast cancer","Antibody-drug conjugates","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krop%20IE%5BAuthor%5D%20trastuzumab%20emtansine%20OR%20deruxtecan"}],"papers":[{"title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30312-1"},{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer (DESTINY-Breast03)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115022"}],"orcid":"0000-0002-6380-5944"},"route":"/people/ian-krop/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"institution":[{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/"}],"trial":[{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/"}],"paper":[{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/"}]}}